Wen-Jie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wen-Jie Wang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Lianqiu Wu
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
4 shared publications Yang Liu
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 shared publications- An-Jun Deng
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2 shared publications - Hai-Lin Qin
State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 China
2 shared publications Lin Wang
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100050, China
2 shared publicationsShan-Ying Peng
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100050, China
2 shared publications
Latest Publications
- Open Access
The Anti-Allergic Rhinitis Effect of Traditional Chinese Medicine of Shenqi by Regulating Mast Cell Degranulation and Th1/Th2 Cytokine Balance
Shenqi is a traditional Chinese polyherbal medicine has been widely used for the treatment of allergic rhinitis (AR). The aim of this study was to investigate the anti-allergic rhinitis activity of Shenqi and explore its underlying molecular mechanism. Ovalbumin (OVA)-induced allergic rhinitis rat model was used to evaluate the anti-allergic rhinitis effect of Shenqi. The effect of Shenqi on IgE-mediated degranulation was measured using rat basophilic leukemia (RBL-2H3) cells. Primary spleen lymphocytes were isolated to investigate the anti-allergic mechanism of Shenqi by detecting the expression of transcription factors via Western blot and the level of cytokines (IL-4 and IFN-γ) via ELISA. In OVA-induced AR rat models, Shenqi relieved the allergic rhinitis symptoms, inhibited the histopathological changes of nasal mucosa, and reduced the levels of IL-4 and IgE. The results from the in vitro study certified that Shenqi inhibited mast cell degranulation. Furthermore, the results of GATA3, T-bet, p-STAT6, and SOCS1 expression and production of IFN-γ and IL-4 demonstrated that Shenqi balanced the ratio of Th1/Th2 (IFN-γ/IL-4) in OVA-stimulated spleen lymphocytes. In conclusion, these results suggest that Shenqi exhibits an obvious anti-allergic effect by suppressing the mast cell-mediated allergic response and by improving the imbalance of Th1/Th2 ratio in allergic rhinitis.
Open AccessThe Anti-Allergic Rhinitis Effect of Traditional Chinese Medicine of Shenqi by Regulating Mast Cell Degranulation and Th1/Th2 Cytokine Balance
Shenqi is a traditional Chinese polyherbal medicine has been widely used for the treatment of allergic rhinitis (AR). The aim of this study was to investigate the anti-allergic rhinitis activity of Shenqi and explore its underlying molecular mechanism. Ovalbumin (OVA)-induced allergic rhinitis rat model was used to evaluate the anti-allergic rhinitis effect of Shenqi. The effect of Shenqi on IgE-mediated degranulation was measured using rat basophilic leukemia (RBL-2H3) cells. Primary spleen lymphocytes were isolated to investigate the anti-allergic mechanism of Shenqi by detecting the expression of transcription factors via Western blot and the level of cytokines (IL-4 and IFN-γ) via ELISA. In OVA-induced AR rat models, Shenqi relieved the allergic rhinitis symptoms, inhibited the histopathological changes of nasal mucosa, and reduced the levels of IL-4 and IgE. The results from the in vitro study certified that Shenqi inhibited mast cell degranulation. Furthermore, the results of GATA3, T-bet, p-STAT6, and SOCS1 expression and production of IFN-γ and IL-4 demonstrated that Shenqi balanced the ratio of Th1/Th2 (IFN-γ/IL-4) in OVA-stimulated spleen lymphocytes. In conclusion, these results suggest that Shenqi exhibits an obvious anti-allergic effect by suppressing the mast cell-mediated allergic response and by improving the imbalance of Th1/Th2 ratio in allergic rhinitis.
- 1 June 2016
- Published by Springer Nature in Pharmacological Reports
- Vol. 68 (3) , 514-520
The protective effect of epicatechin on experimental ulcerative colitis in mice is mediated by increasing antioxidation and by the inhibition of NF-κB pathway
Ulcerative colitis (UC) is a chronic inflammatory intestinal disease. It is necessary to find out new effective drugs for UC. In our study epicatechin extracted from grape seed by our institute for the first time could treat UC effectively. Then anti-UC mechanisms of epicatechin were elucidated in vivo and in vitro. Dextran sulfate sodium (DSS)-induced acute UC mice model was used to evaluate the activity of epicatechin and its properties against UC. Then its anti-inflammatory and antioxidant effects were evaluated as follows: the concentrations of TNF-α and IL-6 in the colon supernatants were determined by ELISA. NO and MPO were assayed by Griess method and commercial kit respectively. NF-κB were determined by NF-κB-Dependent Reporter Gene Expression Assay and Western Blotting respectively. Antioxidant factors such as SOD, MDA, GSH-Px and CAT were also measured in colon tissues and cell supernatant stimulated by LPS respectively. In C57BL/6J mice model with DSS-induced UC, epicatechin was able to decrease the disease activity index and colon macroscopic damage index scores, reduce body weight loss, and significantly relieve colon contracture and crypt damage. TNF-α, IL-6, NO, MPO and MDA were reduced in the mice administered epicatechin, whereas antioxidant enzymes showed increased activity in epicatechin-treated mice and cell line respectively. Furthermore, inhibition effect on NF-κB activation by epicatechin were demonstrated in vivo and in vitro. Epicatechin has inhibitory effect on DSS-induced acute UC. This effect is mainly due to its antioxidant effect and the inhibition of inflammatory molecules related to NF-κB pathway.
- 1 June 2016
- Published by Springer Nature in Pharmacological Reports
- Vol. 68 (3) , 514-520
The protective effect of epicatechin on experimental ulcerative colitis in mice is mediated by increasing antioxidation and by the inhibition of NF-κB pathway
Ulcerative colitis (UC) is a chronic inflammatory intestinal disease. It is necessary to find out new effective drugs for UC. In our study epicatechin extracted from grape seed by our institute for the first time could treat UC effectively. Then anti-UC mechanisms of epicatechin were elucidated in vivo and in vitro. Dextran sulfate sodium (DSS)-induced acute UC mice model was used to evaluate the activity of epicatechin and its properties against UC. Then its anti-inflammatory and antioxidant effects were evaluated as follows: the concentrations of TNF-α and IL-6 in the colon supernatants were determined by ELISA. NO and MPO were assayed by Griess method and commercial kit respectively. NF-κB were determined by NF-κB-Dependent Reporter Gene Expression Assay and Western Blotting respectively. Antioxidant factors such as SOD, MDA, GSH-Px and CAT were also measured in colon tissues and cell supernatant stimulated by LPS respectively. In C57BL/6J mice model with DSS-induced UC, epicatechin was able to decrease the disease activity index and colon macroscopic damage index scores, reduce body weight loss, and significantly relieve colon contracture and crypt damage. TNF-α, IL-6, NO, MPO and MDA were reduced in the mice administered epicatechin, whereas antioxidant enzymes showed increased activity in epicatechin-treated mice and cell line respectively. Furthermore, inhibition effect on NF-κB activation by epicatechin were demonstrated in vivo and in vitro. Epicatechin has inhibitory effect on DSS-induced acute UC. This effect is mainly due to its antioxidant effect and the inhibition of inflammatory molecules related to NF-κB pathway.
- 1 March 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 32, 16-23
The antinociceptive effect and mechanism of action of SY0916
- 1 March 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 32, 16-23
The antinociceptive effect and mechanism of action of SY0916
- 1 October 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 86, 542-549
Syntheses and structure–activity relationships in cytotoxicities of 13-substituted quaternary coptisine derivatives
- 1 October 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 86, 542-549
Syntheses and structure–activity relationships in cytotoxicities of 13-substituted quaternary coptisine derivatives
- 31 March 2013
- Published by Elsevier in Fitoterapia
- Vol. 85, 101-108
Osteoclast-inhibiting saikosaponin derivatives from Bupleurum Chinense
- 31 March 2013
- Published by Elsevier in Fitoterapia
- Vol. 85, 101-108
Osteoclast-inhibiting saikosaponin derivatives from Bupleurum Chinense
- 10 October 2011
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 13 (11) , 984-992
Inhibitory effects of SY0916, a platelet-activating factor receptor antagonist, on the angiogenesis of human umbilical vascular endothelial cells
SY0916 is a novel platelet-activating factor receptor antagonist. The objective of this study is to explore the anti-angiogenesis effects of SY0916 on human umbilical vascular endothelial cell (HUVEC) and to understand its possible mechanism. The effect of SY0916 on proliferation of HUVEC was measured by the MTT method, whereas the effect of SY0916 on HUVEC chemotaxis was carried out by Boyden chamber assay. The activities of metalloproteinase (MMP)-9 and MMP-2 were detected using gelatin zymography, and the expression of intercellular adhesion molecules-1 (ICAM-1) was measured by Western blot analysis. The 2D tube formation experiment of HUVEC with 10% fetal calf serum on Matrigel was also evaluated. It was shown that SY0916 had significant inhibitory effects on the proliferation and the chemotaxis of HUVEC induced by phorbol-12-myristate-13-acetate in a positive dose-dependent manner. Furthermore, SY0916 could significantly suppress the activity of MMP-2 and MMP-9 and decrease the expression of ICAM-1 in HUVEC. In 2D tube formation test, SY0916 could effectively inhibit the formation of vascular structure on Matrigel. The results showed that SY0916 could block the chemotaxis of HUVEC, and then inhibit the tube formation on Matrigel. Such anti-angiogenesis effect of SY0916 on HUVEC might relate to downregulate the expressions of MMP-2, MMP-9, and ICAM-1.
- 10 October 2011
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 13 (11) , 984-992
Inhibitory effects of SY0916, a platelet-activating factor receptor antagonist, on the angiogenesis of human umbilical vascular endothelial cells
SY0916 is a novel platelet-activating factor receptor antagonist. The objective of this study is to explore the anti-angiogenesis effects of SY0916 on human umbilical vascular endothelial cell (HUVEC) and to understand its possible mechanism. The effect of SY0916 on proliferation of HUVEC was measured by the MTT method, whereas the effect of SY0916 on HUVEC chemotaxis was carried out by Boyden chamber assay. The activities of metalloproteinase (MMP)-9 and MMP-2 were detected using gelatin zymography, and the expression of intercellular adhesion molecules-1 (ICAM-1) was measured by Western blot analysis. The 2D tube formation experiment of HUVEC with 10% fetal calf serum on Matrigel was also evaluated. It was shown that SY0916 had significant inhibitory effects on the proliferation and the chemotaxis of HUVEC induced by phorbol-12-myristate-13-acetate in a positive dose-dependent manner. Furthermore, SY0916 could significantly suppress the activity of MMP-2 and MMP-9 and decrease the expression of ICAM-1 in HUVEC. In 2D tube formation test, SY0916 could effectively inhibit the formation of vascular structure on Matrigel. The results showed that SY0916 could block the chemotaxis of HUVEC, and then inhibit the tube formation on Matrigel. Such anti-angiogenesis effect of SY0916 on HUVEC might relate to downregulate the expressions of MMP-2, MMP-9, and ICAM-1.
- 8 March 2010
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (4) , 470-475
Effects and mechanism of aromatic aminoketone SY0916 on osteoclastic bone destruction
Aim: Methods: Results: Conclusion:
- 8 March 2010
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (4) , 470-475
Effects and mechanism of aromatic aminoketone SY0916 on osteoclastic bone destruction
Aim: Methods: Results: Conclusion: